{"id":58014,"date":"2026-02-26T16:17:21","date_gmt":"2026-02-26T08:17:21","guid":{"rendered":"https:\/\/flcube.com\/?p=58014"},"modified":"2026-03-06T13:58:39","modified_gmt":"2026-03-06T05:58:39","slug":"fosun-pharmas-luvometinib-cleared-for-phase-ii-nsclc-combination-trial-mek-inhibitor-plus-anlotinib-targets-kras-mutations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58014","title":{"rendered":"Fosun Pharma’s Luvometinib Cleared for Phase II NSCLC Combination Trial \u2013 MEK Inhibitor Plus Anlotinib Targets KRAS Mutations"},"content":{"rendered":"\n

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG:\u202f2196<\/a>, SHA:\u202f600196<\/a>)<\/strong> announced NMPA approval<\/strong> to initiate a Phase II clinical trial<\/strong> evaluating Fumaining (Luvometinib)<\/strong>, a selective MEK1\/2 inhibitor<\/strong>, in combination with anlotinib<\/strong> for advanced non\u2011small cell lung cancer (NSCLC)<\/strong> patients with KRAS mutations<\/strong>. The study expands Luvometinib’s oncology applications beyond its approved indications in Langerhans cell histiocytosis (LCH) and neurofibromatosis type\u202f1 (NF1)<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Shanghai Fosun Pharmaceutical (HKG:\u202f2196, SHA:\u202f600196)<\/td><\/tr>
Product<\/strong><\/td>Fumaining (Luvometinib) \u2013 selective MEK1\/2 inhibitor<\/td><\/tr>
Regulatory Action<\/strong><\/td>NMPA approval for Phase II combination trial<\/td><\/tr>
Combination Partner<\/strong><\/td>Anlotinib (VEGFR\u2011targeted TKI)<\/td><\/tr>
Study Population<\/strong><\/td>Advanced NSCLC with KRAS mutations<\/td><\/tr>
Development Origin<\/strong><\/td>Independently developed by Fosun Pharma<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Luvometinib Approved & Pending Indications<\/h2>\n\n\n\n
Status<\/th>Indication<\/th>Patient Population<\/th><\/tr><\/thead>
Approved (China)<\/strong><\/td>Langerhans cell histiocytosis (LCH) + histiocytic neoplasms<\/td>Adults<\/td><\/tr>
Approved (China)<\/strong><\/td>Symptomatic, inoperable plexiform neurofibromas (PN)<\/td>Pediatrics\/adolescents \u2265\u202f2 years (NF1)<\/td><\/tr>
NDA Accepted \u2013 Priority Review<\/strong><\/td>Langerhans cell histiocytosis (LCH)<\/td>Pediatrics \u2265\u202f2 years<\/td><\/tr>
NDA Accepted \u2013 Priority Review<\/strong><\/td>Symptomatic, inoperable PN<\/td>Adults (NF1)<\/td><\/tr>
Phase III Ongoing<\/strong><\/td>Pediatric low\u2011grade gliomas<\/td>Children<\/td><\/tr>
Phase II Ongoing<\/strong><\/td>Extracranial arteriovenous malformations<\/td>All ages<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale \u2013 NSCLC Combination<\/h2>\n\n\n\n
Component<\/th>Mechanism<\/th>Synergy Potential<\/th><\/tr><\/thead>
Luvometinib (MEK1\/2 inhibitor)<\/strong><\/td>Blocks MAPK pathway downstream of KRAS<\/td>Targets KRAS\u2011driven tumor proliferation<\/td><\/tr>
Anlotinib (VEGFR TKI)<\/strong><\/td>Inhibits angiogenesis and tumor vascularization<\/td>Disrupts tumor blood supply; potential enhancement of MEK inhibitor delivery<\/td><\/tr>
Combined Effect<\/strong><\/td>Dual blockade of MAPK signaling + anti\u2011angiogenesis<\/td>Addresses KRAS mutation heterogeneity and resistance mechanisms<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

KRAS NSCLC Context<\/h2>\n\n\n\n
Parameter<\/th>Detail<\/th><\/tr><\/thead>
KRAS Mutation Prevalence<\/strong><\/td>~\u202f25% of NSCLC cases; G12C most common subtype<\/td><\/tr>
Standard of Care<\/strong><\/td>KRAS G12C inhibitors (sotorasib, adagrasib) for specific mutations; limited options for non\u2011G12C KRAS variants<\/td><\/tr>
Unmet Need<\/strong><\/td>Effective therapies for KRAS mutations beyond G12C; combination strategies to overcome resistance<\/td><\/tr>
MEK Inhibitor Rationale<\/strong><\/td>Downstream MAPK inhibition active across KRAS mutation subtypes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n